STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Agenus Announces Virtual Annual Shareholders Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 17, 2025

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2025.

Voting Information:

Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus’s proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@AllianceAdvisors.com.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Investors

917-362-1370

investor@agenusbio.com



Media

781-674-4422

communications@agenusbio.com

Source: Agenus Inc.

Agenus

NASDAQ:AGEN

AGEN Rankings

AGEN Latest News

AGEN Latest SEC Filings

AGEN Stock Data

121.40M
31.30M
1.71%
30.11%
8.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON